Status:
RECRUITING
Quantifying New Heart Muscle Cells
Lead Sponsor:
Weill Medical College of Cornell University
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
California Institute of Technology
Conditions:
Tetralogy of Fallot With Pulmonary Stenosis
Heart Failure
Eligibility:
All Genders
30-1 years
Phase:
NA
Brief Summary
Regenerative therapies could provide new ways of treating heart failure. Unlike many organs in the human body, such as the skin and the GI tract, the ability to regenerate heart muscle decreases after...
Eligibility Criteria
Inclusion
- Patients at 30 days of age to 1 year of age undergoing scheduled elective cardiac surgery will be eligible for study inclusion.
- The investigators will recruit patients at 30 days of age to 1 year of age with those types of heart disease whose surgical approach has a high probability of myocardial resection.
- Diagnosis of ToF/PS or other types of heart disease that have a high likelihood of requiring surgery that involves routine resection of myocardium that becomes available for research
Exclusion
- Patients with low chance of having resection of myocardium as part of their surgical care.
Key Trial Info
Start Date :
July 23 2015
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06587165
Start Date
July 23 2015
End Date
March 1 2027
Last Update
July 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Weill Cornell Medicine
New York, New York, United States, 10065